

Illinois Department of Public Health

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  <b>IL6000434</b>	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____  B. WING _____	(X3) DATE SURVEY COMPLETED  <b>07/07/2022</b>
--	--	---	---

NAME OF PROVIDER OR SUPPLIER  <b>ALLURE OF GALESBURG</b>	STREET ADDRESS, CITY, STATE, ZIP CODE <b>1145 FRANK STREET GALESBURG, IL 61401</b>
--	---

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
S 000	Initial Comments  Annual Licensure Survey	S 000		
S9999	Final Observations  Statement of Licensure Violations  300.686 a.)2)7)10) 300.686 b)1)2)4) 300.686 c) 300.686 d)  Section 300.686 Unnecessary, Psychotropic, and Antipsychotic Medications a) For the purposes of this Section, the following definitions shall apply: 2) "Antipsychotic medication" - a medication that is used to treat symptoms of psychosis such as delusions, hearing voices, hallucinations, paranoia, or confused thoughts. Antipsychotic medications are used in the treatment of schizophrenia, severe depression, and severe anxiety. Older antipsychotic medications tend to be called typical antipsychotics. Those developed more recently are called atypical antipsychotics. 4) "Duplicative therapy" - multiple medications of the same pharmacological class or category or any medication therapy that substantially duplicates a particular effect of another medication that the individual is taking. 7) "Gradual dose reduction" - the stepwise tapering of a dose to determine if symptoms, conditions or risks can be managed by a lower dose or if the dose or medication can be discontinued. 10) "Psychotropic medication" - medication that is used for or listed as used for psychotropic, antidepressant, antimanic or antianxiety behavior modification or behavior management purposes	S9999	<p><b>Attachment A</b> <b>Statement of Licensure Violations</b></p>	

REGULATORY DIRECTOR'S OR PROVIDER/SUPPLIER REPRESENTATIVE'S SIGNATURE	TITLE	(X6) DATE
---	-------	-----------

Illinois Department of Public Health

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  IL6000434	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____  B. WING: _____	(X3) DATE SURVEY COMPLETED  07/07/2022
--	---	--	--

NAME OF PROVIDER OR SUPPLIER  ALLURE OF GALESBURG	STREET ADDRESS, CITY, STATE, ZIP CODE 1145 FRANK STREET GALESBURG, IL 61401
---	---

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
S9999	<p>Continued From page 1</p> <p>in the Prescribers Digital Reference database, the Lexicomp-online database, or the American Society of Health-System Pharmacists database. Psychotropic medication also includes any medication listed in 42 CFR 483.45(c)(3).</p> <p>b) A resident shall not be given unnecessary medications. An unnecessary medication is any drug used:</p> <p>1) In an excessive dose, including in duplicative therapy;</p> <p>2) For excessive duration;</p> <p>4) Without adequate indications for its use;</p> <p>c) Residents shall not be given antipsychotic medications unless antipsychotic medication therapy is ordered by a physician or an authorized prescribing professional, as documented in the resident's comprehensive assessment, to treat a specific symptom or suspected condition as diagnosed and documented in the clinical record or to rule out the possibility of one of the conditions in accordance with Appendix F.</p> <p>d) Residents who use antipsychotic medications shall receive gradual dose reductions and behavior interventions, unless clinically contraindicated, in an effort to discontinue these medications in accordance with Appendix F. In compliance with subsection 2-106.1(b) of the Act and this Section, the facility shall obtain informed consent for each dose reduction.</p> <p>These requirements were not met as evidenced by:</p> <p>Based on observation, interview, and record review, the facility failed to warrant the use of dual antipsychotic therapy and a PRN (as needed) antipsychotic medication, perform GDRs (Gradual Dose Reductions), and ensure a PRN</p>	S9999		

Illinois Department of Public Health

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  IL6000434	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____  B. WING _____	(X3) DATE SURVEY COMPLETED  07/07/2022
--	---	---	--

NAME OF PROVIDER OR SUPPLIER  ALLURE OF GALESBURG	STREET ADDRESS, CITY, STATE, ZIP CODE 1145 FRANK STREET GALESBURG, IL 61401
---	---

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
S9999	<p>Continued From page 2</p> <p>antipsychotic didn't exceed a duration of 14 days without a documented rationale for the extended time period for two of four residents (R4, R5) reviewed for antipsychotics in the sample of eight.</p> <p>Findings include:</p> <p>The facility's Use of Psychotropic Medication policy, dated 2022, documents, "Residents who use psychotropic drugs shall also receive gradual dose reductions, unless clinically contraindicated, in an effort to discontinue these drugs. PRN orders for all psychotropic drugs shall be used only when the medication is necessary to treat a diagnosed specific condition that is documented in the clinical record, and for a limited duration (i.e. 14 days)</p> <p>1. On 7/5/22 at 1:15 pm, R4 was alert and oriented lying on her bed conversing pleasantly with her roommate not displaying any adverse behaviors. R4 was clean and well kept.</p> <p>R4's Care Plan, dated 7/7/22, documents, "I use psychotropic medication related to Schizophrenia." The Care Plan also documents the following intervention: Consult with pharmacy. Physician to consider dosage reduction when clinically appropriate at least quarterly.</p> <p>R4's Order Summary Report, dated 7/6/22, documents that R4 has an order to receive Risperdal (antipsychotic) 3 mg (milligrams) by mouth at bedtime. The report also documents that this medication was ordered on 7/7/21.</p> <p>R4's POC (Point of Care) Response History, dated 7/7/22, documents for the last 30 days (6/8-7/7/22) R4 has not had any adverse behaviors observed.</p>	S9999		

Illinois Department of Public Health

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  IL6000434	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____  B. WING: _____	(X3) DATE SURVEY COMPLETED  07/07/2022
--	---	--	--

NAME OF PROVIDER OR SUPPLIER  ALLURE OF GALESBURG	STREET ADDRESS, CITY, STATE, ZIP CODE 1145 FRANK STREET GALESBURG, IL 61401
---	---

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
S9999	<p>Continued From page 3</p> <p>R4's Medication Regimen Review Prescriber Recommendations, dated 1/5/22 and 6/3/22, documents, "The resident (R4) is receiving Risperdal 3 mg at bedtime for psychosis since 7/7/21. Gradual dosage reductions are periodically recommended for all psychotropics. Alternatively, a prescriber note with clinical rationale for why any an attempted dose reduction would impair function or cause psychiatric instability and exacerbate an underlying medical/psychiatric disorder is also recommended. CMS (Centers for Medicaid and Medicare) guidelines require periodic notification and prescriber documentation related to psychotropic medication use in skilled long term care facilities."</p> <p>On 7/6/22 at 1:05 p.m. V2 (Director of Nursing) confirmed that R4 has not had a GDR of R4's antipsychotic as well as no documentation to warrant not performing a GDR.</p> <p>2. On 7/5/22 at 1:00 p.m., R5 was alert and ambulating independently in the hallway. R5 was not displaying any adverse behaviors, and was clean and well kept.</p> <p>R5's Care plan, dated 7/6/22, documents, "The resident (R5) uses psychotropic medication related to Major Depression, Anxiety, Schizoaffective." The Care Plan also documents the following intervention: Consult with pharmacy. Physician to consider dosage reduction when clinically appropriate at least quarterly.</p> <p>R5's Order Summary report, dated 7/6/22, documents that R5 has orders to receive: Zyprexa (antipsychotic) 10 mg by mouth twice a day related to Schizoaffective disorder that was</p>	S9999		

Illinois Department of Public Health

STATEMENT OF DEFICIENCIES AND PLAN OF CORRECTION	(X1) PROVIDER/SUPPLIER/CLIA IDENTIFICATION NUMBER:  <b>IL6000434</b>	(X2) MULTIPLE CONSTRUCTION A. BUILDING: _____  B. WING _____	(X3) DATE SURVEY COMPLETED  <b>07/07/2022</b>
--	--	---	---

NAME OF PROVIDER OR SUPPLIER  <b>ALLURE OF GALESBURG</b>	STREET ADDRESS, CITY, STATE, ZIP CODE <b>1145 FRANK STREET GALESBURG, IL 61401</b>
--	---

(X4) ID PREFIX TAG	SUMMARY STATEMENT OF DEFICIENCIES (EACH DEFICIENCY MUST BE PRECEDED BY FULL REGULATORY OR LSC IDENTIFYING INFORMATION)	ID PREFIX TAG	PROVIDER'S PLAN OF CORRECTION (EACH CORRECTIVE ACTION SHOULD BE CROSS-REFERENCED TO THE APPROPRIATE DEFICIENCY)	(X5) COMPLETE DATE
S9999	<p>Continued From page 4</p> <p>ordered on 4/20/22; Zyprexa 10 mg by mouth every six hours as needed for agitation that was ordered on 3/30/22; Seroquel 400 mg by mouth twice a day related to Schizoaffective Disorder that was ordered on 4/20/22. The Order Summary report has no documentation of a stop date for R5's PRN Zyprexa.</p> <p>R5's Medication Regimen Review Prescriber Recommendations, dated 4/8/22 and 7/6/22, documents, "The resident (R5) is receiving: Zyprexa 10 mg by mouth every six hours as needed for agitation. CMS guidelines limit all PRN use of antipsychotics to 14 days and require prescriber examination/evaluation every 14 days to renew orders. Report of the resident's condition from staff to the prescribing practitioner does not constitute an evaluation. Please consider: Discontinue Zyprexa tablet and injection PRN or perform evaluations every 14 days to renew orders."</p> <p>On 7/6/22 at 1:20 p.m., V2 stated, "(R5) does not have a stop date for his PRN Zyprexa, and the facility does not have any documentation to justify R5 receiving dual antipsychotics. The target behavior for administering R5's Zyprexa is agitation, and not all agitation is psychotic. (R5's) psychiatry notes do not address (R5's) dual antipsychotics."</p> <p>(B)</p>	S9999		